Menu
More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF). Effective treatment of ACLF is an urgent and unmet need.
The EU-funded A-TANGO project aims to bring a novel treatment (G-TAK) that combines a drug known to targets inflammation (TAK-242) and granulocyte colony-stimulating factor (G-CSF) which improves hepatocyte proliferation. Alongside the identification of novel biomarkers for patient selection and prognosis, G-TAK is expected to improve the clinical outcome of patients with alcohol-reated liver disease who are at high risk to develop ACLF. The A-TANGO Consortium will perform a phase II randomized controlled trial to evaluate the safety and effectiveness of this novel treatment.
Treatment of ACLF is an unmet need. The combinatorial approach of granulocyte colony stimulating factor and a Toll-like receptor 4 antagonist offers the dual benefit of inhibiting systemic inflammation and allowing liver regeneration, which could impact positively on the outcomes of patients with ACLF. The results could dramatically impact the survival of patients with ACLF, a patient population which is responsible for the mortality of over 1 million people world-wide. The trial is being performed in about 20 European hepatology centers linked with EF CLIF and aims to recruit its first patients in the 1st quarter of 2023.
This study received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 945096.
European Foundation for the Study of
Chronic Liver Failure
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain
© European Foundation for the Study of Chronic Liver Failure 2024
